GSK gets CHMP positive opinion for new indication for Arixtra

Published July 27, 2010

GSK gets CHMP positive opinion for new indication for Arixtra
GlaxoSmithKline (GSK) has received positive opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Arixtra (fondaparinux),an anti-clotting drug (antithrombotic) for the treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis (SVT) of the lower limbs without concomitant deep-vein thrombosis.
Read more on PharmaBiz

AIDS Healthcare Foundation Bans BMS Drug Reps from Its Clinics
LOS ANGELES—-Today AIDS Healthcare Foundation announced that it has banned pharmaceutical sales representatives from Bristol-Myers Squibb from calling on AHF’s medical providers and staff in its sixteen U.S. healthcare centers.
Read more on Business Wire via Yahoo! Finance